Company doubled annual profits, achieved 30% revenue growth beating Wall Street estimates, maintains strong balance sheet with $64.8M cash and no debt, and is actively pursuing strategic growth initiatives including acquisitions, new product launches (at-home injections), and pharma partnerships. However, sentiment is tempered by softer Q4 results, modest 2026 guidance (15% growth), and significant stock underperformance (down 60% from 52-week high despite strong fundamentals).
Also mentions NAGE
Articles that tag NAGE but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
